Basic research aiming for clinical application of 5-aminolevulinic acid in musculoskeletal sarcomas

Basic research aiming for clinical application of 5-aminolevulinic acid in musculoskeletal sarcomas - Basic research aiming for clinical application of 5-ALA in musculoskeletal sarcomas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022275

Enrollment

Registered

2020-01-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone and soft tissue sarcomas

Interventions

The administration of 5-aminolevulinic acid (5-ALA)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed as bone or soft tissue sarcoma

Exclusion criteria

Exclusion criteria: 1. Having difficulty in taking medication 2. Still having severe adverse effects of previous treatment for sarcomas 3. Having un-controlled infection 4. Severe complications, such as malignant hypertension, severe congestive heart failure, myocardial infarction within 3 months, terminal cirrhosis, un-controlled diabetes, severe pulmonary fibrosis, active interstitial pneumonia 5. Allergy to porphyrin-related substances 6. Porphyria 7. Other active cancer including hematologic malignancy

Design outcomes

Primary

Measure	Time frame
1. The strength of fluorescent signal induced by PPIX in both cell lines and clinical specimens	—

Secondary

Measure	Time frame
2. The degree of expression of the aforementioned genes in both cell lines and clinical specimens	—

Countries

Japan

Contacts

Public ContactJungo Imanishi

Saitama Medical University International Medical Center ORthopaedic Oncology and Surgery

jungo@saitama-med.ac.jp042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026